



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

May 6, 2022

Luca Santarelli
Chief Executive Officer
VectivBio Holding AG
Aeschenvorstadt 36
4051 Basel
Switzerland

Re: VectivBio Holding AG
Registration Statement on Form F-3
Filed May 4, 2022
File No. 333-264653

Dear Mr. Santarelli:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Brandon Fenn, Esq.